{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,4]],"date-time":"2026-09-04T18:27:45Z","timestamp":1788546465978,"version":"build-2803163510"},"reference-count":21,"publisher":"American Medical Association (AMA)","issue":"12","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["JAMA Cardiol"],"published-print":{"date-parts":[[2024,12,1]]},"abstract":"<jats:sec><jats:title>Importance<\/jats:title><jats:p>Greater splanchnic nerve ablation may improve hemodynamics in patients with heart failure and preserved ejection fraction (HFpEF).<\/jats:p><\/jats:sec><jats:sec><jats:title>Objective<\/jats:title><jats:p>To explore the feasibility and safety of endovascular right-sided splanchnic nerve ablation for volume management (SAVM).<\/jats:p><\/jats:sec><jats:sec><jats:title>Design, Setting, and Participants<\/jats:title><jats:p>This was a phase 2, double-blind, 1:1, sham-controlled, multicenter, randomized clinical trial conducted at 14 centers in the US and 1 center in the Republic of Georgia. Patients with HFpEF, left ventricular ejection fraction of 40% or greater, and invasively measured peak exercise pulmonary capillary wedge pressure (PCWP) of 25 mm Hg or greater were included. Study data were analyzed from May 2023 to June 2024.<\/jats:p><\/jats:sec><jats:sec><jats:title>Intervention<\/jats:title><jats:p>SAVM vs sham control procedure.<\/jats:p><\/jats:sec><jats:sec><jats:title>Main Outcomes and Measures<\/jats:title><jats:p>The primary efficacy end point was a reduction in legs-up and exercise PCWP at 1 month. The primary safety end point was serious device- or procedure-related adverse events at 1 month. Secondary efficacy end points included HF hospitalizations, changes in exercise function and health status through 12 months, and baseline to 1-month change in resting, legs-up, and 20-W exercise PCWP.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>A total of 90 patients (median [range] age, 71 [47-90] years; 58 female [64.4%]) were randomized at 15 centers (44 SAVM vs 46 sham). There were no differences in adverse events between groups. The primary efficacy end point did not differ between SAVM or sham (mean between-group difference in PCWP, \u22120.03 mm Hg; 95% CI, \u22122.5 to 2.5 mm Hg; <jats:italic>P<\/jats:italic>\u2009=\u2009.95). There were also no differences in the secondary efficacy end points. There was no difference in the primary safety end point between the treatment (6.8% [3 of 44]) and sham (2.2% [1 of 46]) groups (difference, 4.6%; 95% CI, \u22126.1% to 15.4%; <jats:italic>P<\/jats:italic>\u2009=\u2009.36). There was no difference in the incidence of orthostatic hypotension between the treatment (11.4% [5 of 44]) and sham (6.5% [3 of 46]) groups (difference, 4.9%; 95% CI, \u22129.2% to 18.8%; <jats:italic>P<\/jats:italic>\u2009=\u2009.48).<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusions and Relevance<\/jats:title><jats:p>Results show that SAVM was safe and technically feasible, but it did not reduce exercise PCWP at 1 month or improve clinical outcomes at 12 months in a broad population of patients with HFpEF.<\/jats:p><\/jats:sec><jats:sec><jats:title>Trial Registration<\/jats:title><jats:p>ClinicalTrials.gov Identifier: <jats:ext-link xmlns:xlink=\"http:\/\/www.w3.org\/1999\/xlink\" ext-link-type=\"uri\" xlink:href=\"https:\/\/clinicaltrials.gov\/study\/NCT04592445\">NCT04592445<\/jats:ext-link><\/jats:p><\/jats:sec>","DOI":"10.1001\/jamacardio.2024.2612","type":"journal-article","created":{"date-parts":[[2024,10,2]],"date-time":"2024-10-02T15:37:39Z","timestamp":1727883459000},"page":"1143","source":"Crossref","is-referenced-by-count":29,"title":["Endovascular Ablation of the Greater Splanchnic Nerve in Heart Failure With Preserved Ejection Fraction"],"prefix":"10.1001","volume":"9","author":[{"given":"Marat","family":"Fudim","sequence":"first","affiliation":[{"name":"Duke University Medical Center Durham, North Carolina"},{"name":"Duke Clinical Research Institute, Durham, North Carolina"},{"name":"Institute of Heart Diseases, Wroclaw Medical University, Wroc\u0142aw, Poland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Barry A.","family":"Borlaug","sequence":"additional","affiliation":[{"name":"Mayo Clinic, College of Medicine, Rochester, Minnesota"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rajeev C.","family":"Mohan","sequence":"additional","affiliation":[{"name":"Scripps Clinic, La Jolla, California"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Matthew J.","family":"Price","sequence":"additional","affiliation":[{"name":"Scripps Clinic, La Jolla, California"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peter","family":"Fail","sequence":"additional","affiliation":[{"name":"Cardiovascular Institute of the South, Houma, Louisiana"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Parag","family":"Goyal","sequence":"additional","affiliation":[{"name":"Weill Cornell Medicine, New Yok, New York"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Scott L.","family":"Hummel","sequence":"additional","affiliation":[{"name":"University of Michigan and VA Ann Arbor, Ann Arbor"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Teona","family":"Zirakashvili","sequence":"additional","affiliation":[{"name":"Tbilisi Heart and Vascular Clinic, Tbilisi, Georgia"},{"name":"AIlia State University, Tbilisi, Georgia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tamaz","family":"Shaburishvili","sequence":"additional","affiliation":[{"name":"Tbilisi Heart and Vascular Clinic, Tbilisi, Georgia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ravi B.","family":"Patel","sequence":"additional","affiliation":[{"name":"Division of Cardiology, Department of Medicine, Northwestern University Feinberg School of Medicine, Chicago, Illinois"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vivek Y.","family":"Reddy","sequence":"additional","affiliation":[{"name":"Mount Sinai Fuster Heart Hospital - Icahn School of Medicine at Mount Sinai, New York, New York"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christopher D.","family":"Nielsen","sequence":"additional","affiliation":[{"name":"Medical University of South Carolina, and Ralph H. Johnson Veterans Affairs Medical Center, Charleston"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stanley J.","family":"Chetcuti","sequence":"additional","affiliation":[{"name":"University of Michigan and VA Ann Arbor, Ann Arbor"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Devraj","family":"Sukul","sequence":"additional","affiliation":[{"name":"University of Michigan and VA Ann Arbor, Ann Arbor"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rajiv","family":"Gulati","sequence":"additional","affiliation":[{"name":"Mayo Clinic, College of Medicine, Rochester, Minnesota"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Luke","family":"Kim","sequence":"additional","affiliation":[{"name":"Weill Cornell Medicine, New Yok, New York"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Keith","family":"Benzuly","sequence":"additional","affiliation":[{"name":"Division of Cardiology, Department of Medicine, Northwestern University Feinberg School of Medicine, Chicago, Illinois"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sumeet S.","family":"Mitter","sequence":"additional","affiliation":[{"name":"Inova Schar Heart and Vascular, Falls Church, Virginia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Liviu","family":"Klein","sequence":"additional","affiliation":[{"name":"University of California San Francisco, San Francisco"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nir","family":"Uriel","sequence":"additional","affiliation":[{"name":"New York-Presbyterian, Columbia University Irving Medical Center, New York"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ralph S.","family":"Augostini","sequence":"additional","affiliation":[{"name":"The Ohio State University Wexner Medical Center, Columbus"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"John E.","family":"Blair","sequence":"additional","affiliation":[{"name":"Univeristy of Washington, Seattle"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Krishna","family":"Rocha-Singh","sequence":"additional","affiliation":[{"name":"Prairie Heart Institute at St John\u2019s Hospital, Springfield, Illinois"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniel","family":"Burkhoff","sequence":"additional","affiliation":[{"name":"Cardiovascular Research Foundation, New York, New York"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Manesh R.","family":"Patel","sequence":"additional","affiliation":[{"name":"Duke University Medical Center Durham, North Carolina"},{"name":"Duke Clinical Research Institute, Durham, North Carolina"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sami I.","family":"Somo","sequence":"additional","affiliation":[{"name":"Axon Therapies, Santa Clara, California"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sheldon E.","family":"Litwin","sequence":"additional","affiliation":[{"name":"Medical University of South Carolina, and Ralph H. Johnson Veterans Affairs Medical Center, Charleston"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sanjiv J.","family":"Shah","sequence":"additional","affiliation":[{"name":"Division of Cardiology, Department of Medicine, Northwestern University Feinberg School of Medicine, Chicago, Illinois"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"10","reference":[{"issue":"10330","key":"hoi240048r1","doi-asserted-by":"publisher","first-page":"1130","DOI":"10.1016\/S0140-6736(22)00016-2","article-title":"Atrial shunt device for heart failure with preserved and mildly reduced ejection fraction (REDUCE LAP-HF II): a randomized, multicenter, blinded, sham-controlled trial.","volume":"399","author":"Shah","year":"2022","journal-title":"Lancet"},{"issue":"10","key":"hoi240048r2","doi-asserted-by":"publisher","first-page":"1648","DOI":"10.1002\/ejhf.2254","article-title":"Obesity, venous capacitance, and venous compliance in heart failure with preserved ejection fraction.","volume":"23","author":"Sorimachi","year":"2021","journal-title":"Eur J Heart Fail"},{"issue":"8","key":"hoi240048r3","doi-asserted-by":"publisher","DOI":"10.1161\/JAHA.117.006817","article-title":"Role of volume redistribution in the congestion of heart failure.","volume":"6","author":"Fudim","year":"2017","journal-title":"J Am Heart Assoc"},{"issue":"1","key":"hoi240048r4","doi-asserted-by":"publisher","DOI":"10.1161\/CIRCHEARTFAILURE.120.007308","article-title":"Extracardiac abnormalities of preload reserve: mechanisms underlying exercise limitation in heart failure with preserved ejection fraction, autonomic dysfunction, and liver disease.","volume":"14","author":"Fudim","year":"2021","journal-title":"Circ Heart Fail"},{"issue":"5","key":"hoi240048r5","doi-asserted-by":"publisher","first-page":"669","DOI":"10.1161\/CIRCHEARTFAILURE.111.961789","article-title":"Sympathetically mediated changes in capacitance: redistribution of the venous reservoir as a cause of decompensation.","volume":"4","author":"Fallick","year":"2011","journal-title":"Circ Heart Fail"},{"issue":"5 Pt 2","key":"hoi240048r6","doi-asserted-by":"publisher","first-page":"H1819","DOI":"10.1152\/ajpheart.1993.265.5.H1819","article-title":"Why does pulmonary venous pressure rise after onset of LV dysfunction: a theoretical analysis.","volume":"265","author":"Burkhoff","year":"1993","journal-title":"Am J Physiol"},{"issue":"48","key":"hoi240048r7","doi-asserted-by":"publisher","first-page":"4255","DOI":"10.1093\/eurheartj\/ehy682","article-title":"Splanchnic nerve block for decompensated chronic heart failure: splanchnic-HF.","volume":"39","author":"Fudim","year":"2018","journal-title":"Eur Heart J"},{"issue":"9","key":"hoi240048r8","doi-asserted-by":"publisher","first-page":"951","DOI":"10.1161\/CIRCULATIONAHA.118.035260","article-title":"Splanchnic nerve block for acute heart failure.","volume":"138","author":"Fudim","year":"2018","journal-title":"Circulation"},{"issue":"9","key":"hoi240048r9","doi-asserted-by":"publisher","first-page":"742","DOI":"10.1016\/j.jchf.2020.04.010","article-title":"Splanchnic nerve block for chronic heart failure.","volume":"8","author":"Fudim","year":"2020","journal-title":"JACC Heart Fail"},{"issue":"4","key":"hoi240048r10","doi-asserted-by":"publisher","first-page":"594","DOI":"10.1002\/ejhf.2829","article-title":"Splanchnic nerve block with botulinum toxin for therapy of chronic heart failure\u2014mechanism of action (SPONGE-HF).","volume":"25","author":"Fudim","year":"2023","journal-title":"Eur J Heart Fail"},{"issue":"3","key":"hoi240048r11","doi-asserted-by":"publisher","first-page":"319","DOI":"10.1016\/j.jacbts.2022.02.005","article-title":"Splanchnic nerve ablation for volume management in heart failure.","volume":"7","author":"Fudim","year":"2022","journal-title":"JACC Basic Transl Sci"},{"issue":"4","key":"hoi240048r12","doi-asserted-by":"publisher","first-page":"293","DOI":"10.1016\/j.jchf.2020.12.006","article-title":"Splanchnic nerve block mediated changes in stressed blood volume in heart failure.","volume":"9","author":"Fudim","year":"2021","journal-title":"JACC Heart Fail"},{"issue":"10","key":"hoi240048r13","doi-asserted-by":"publisher","first-page":"744","DOI":"10.1016\/j.jchf.2022.05.009","article-title":"Transvenous right greater splanchnic nerve ablation in heart failure and preserved ejection fraction: first-in-human study.","volume":"10","author":"Fudim","year":"2022","journal-title":"JACC Heart Fail"},{"issue":"7","key":"hoi240048r14","doi-asserted-by":"publisher","first-page":"877","DOI":"10.1016\/j.cardfail.2023.12.010","article-title":"Endovascular ablation of the right greater splanchnic nerve in heart failure with preserved ejection fraction: rationale, design, and lead-in phase results of the REBALANCE-HF trial.","volume":"30","author":"Fudim","year":"2024","journal-title":"J Card Fail"},{"issue":"8","key":"hoi240048r15","doi-asserted-by":"publisher","first-page":"1410","DOI":"10.1002\/ejhf.2559","article-title":"Endovascular ablation of the right greater splanchnic nerve in heart failure with preserved ejection fraction: early results of the REBALANCE-HF trial roll-in cohort.","volume":"24","author":"Fudim","year":"2022","journal-title":"Eur J Heart Fail"},{"issue":"4","key":"hoi240048r16","doi-asserted-by":"publisher","first-page":"364","DOI":"10.1161\/CIRCULATIONAHA.117.032094","article-title":"Transcatheter interatrial shunt device for the treatment of heart failure with preserved ejection fraction (REDUCE LAP-HF I [reduce elevated left atrial pressure in patients with heart failure]): a phase 2, randomized, sham-controlled trial.","volume":"137","author":"Feldman","year":"2018","journal-title":"Circulation"},{"issue":"6","key":"hoi240048r17","doi-asserted-by":"publisher","first-page":"742","DOI":"10.1161\/CIRCHEARTFAILURE.112.969154","article-title":"Evaluating treatment efficacy by multiple end points in phase II acute heart failure clinical trials: analyzing data using a global method.","volume":"5","author":"Sun","year":"2012","journal-title":"Circ Heart Fail"},{"issue":"7","key":"hoi240048r18","doi-asserted-by":"publisher","first-page":"1076","DOI":"10.1002\/ejhf.2196","article-title":"Splanchnic nerve modulation in heart failure: mechanistic overview, initial clinical experience, and safety considerations.","volume":"23","author":"Fudim","year":"2021","journal-title":"Eur J Heart Fail"},{"issue":"18","key":"hoi240048r19","doi-asserted-by":"publisher","first-page":"1858","DOI":"10.1016\/j.jacc.2022.02.050","article-title":"Venous tone and stressed blood volume in heart failure: JACC review topic of the week.","volume":"79","author":"Fudim","year":"2022","journal-title":"J Am Coll Cardiol"},{"issue":"15","key":"hoi240048r20","doi-asserted-by":"publisher","first-page":"1952","DOI":"10.1016\/j.jacc.2021.02.048","article-title":"Greater splanchnic nerve stimulation in heart failure with preserved ejection fraction.","volume":"77","author":"Fudim","year":"2021","journal-title":"J Am Coll Cardiol"},{"key":"hoi240048r21","author":"Kim","year":"2024"}],"container-title":["JAMA Cardiology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/jamanetwork.com\/journals\/jamacardiology\/articlepdf\/2823999\/jamacardiology_fudim_2024_oi_240048_1733417067.29711.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,12,11]],"date-time":"2024-12-11T20:36:34Z","timestamp":1733949394000},"score":1,"resource":{"primary":{"URL":"https:\/\/jamanetwork.com\/journals\/jamacardiology\/fullarticle\/2823999"}},"subtitle":["The REBALANCE-HF Randomized Clinical Trial"],"short-title":[],"issued":{"date-parts":[[2024,12,1]]},"references-count":21,"journal-issue":{"issue":"12","published-print":{"date-parts":[[2024,12,1]]}},"URL":"https:\/\/doi.org\/10.1001\/jamacardio.2024.2612","relation":{},"ISSN":["2380-6583"],"issn-type":[{"value":"2380-6583","type":"print"}],"subject":[],"published":{"date-parts":[[2024,12,1]]}}}